郑州做近视眼多少钱郑州近视矫正,郑州眼科医院电话,郑州河南最好的眼科在哪里,郑州斜视眼纠正手术,郑州做近视激光需要多少钱,郑州郑州专门看眼的医院,郑州濮阳眼睛专科医院

BEIJING, Dec. 12 (Xinhuanet) -- For many multinational firms, the past 10 years in China have not only marked the rise of the world's second-largest economy but have also been a decade of expansion and profit growth.As they look back at this "golden decade", which is often used to describe the days after China entered the World Trade Organization (WTO) in 2001, their early expectations and ambitions in a more liberalized Chinese market were found to be more than fulfilled.When German auto giant BMW set foot on the Chinese mainland by establishing its first office in Beijing in 1994, its products were still far too luxurious for ordinary Chinese.In 2001, only 6,500 vehicles were sold under the BMW and Mini brands in China.NYK Diana, a container ship, anchors at Qingdao Port in East China's Shandong province on Thursday, as workers load cargo.But sales started to pick up with China's WTO entry, when the removal of trade barriers brought unprecedented economic growth and a booming market.In 2010, the vehicle maker, which started a joint venture with the domestic Brilliance China Automotive in 2003, sold 169,000 vehicles in China.That record is set to be broken this year as more than 170,000 cars were sold only in the first three quarters."We are both beneficiaries and firm supporters of the open market system," said Christoph Stark, president and CEO of BMW's Greater China region.By liberalizing its market, China, which celebrated the 10th anniversary of its WTO accession on Sunday, has become a thriving market and a savior for foreign enterprises hit hard by the global downturn.In 2009, when General Motors declared bankruptcy in the United States amid the global recession, its Chinese branch saw sales rise 66.9 percent year-on-year to more than 1.8 million units.In 2010, China overtook the United States to become GM's largest national market.The list of similar companies is extensive, as China's decade-long membership of the WTO has helped the Asian powerhouse attract 347,000 foreign firms with investment of more than 0 billion in the past 10 years.Chong Quan, deputy representative for China's international trade talks, said foreign enterprises made more than 0 billion in profit in the 10-year period, with an average annual increase of 30 percent."The accession to the WTO has made China a more transparent, safe and predictable market, as well as an essential part of the global economy," said Dominique Poulique, president of Alstom China.The French power engineering and train company, with more than 30 entities and about 10,000 employees in China, is one of the major foreign suppliers to the Chinese rail transport market."Rapid changes took place in China in the past decade, with its massive investment in infrastructure construction and notable development in energy," Poulique said.Wang Zhile, director of the research center of transnational cooperation under the Ministry of Commerce, said increasing shared interests between China and multinationals are putting them into an inseparable community, one that has found win-win solutions in the past decade.There is also high-quality labor at a relatively low cost, including white-collar workers, he added.Admittedly, the huge market and rich resources have powered up multinational firms in global competition, especially during and after the financial crisis.Forty-nine percent of the responding multinational companies had higher expectations for China in the wake of the global financial crisis in 2008 and 2009, according to a recent survey by the Economist Intelligence Unit, a business information arm of the Economist Group.Although showing signs of a slowdown, China's economy is still widely expected to grow by more than 8 percent next year, at a time when debt and financial instability are weakening growth in other leading economies.Poulique said he expected China's rapid growth to continue into the next decade, especially in the infrastructure construction market."For Alstom, the top task here is to keep adapting to the changing business environment," he said.Many foreign companies are moving research and development facilities to China in the hopes of making it a base for talent and technology.In Shanghai, 347 multinationals have set up regional headquarters, with the establishment of 333 foreign-funded research and development centers.

BEIJING, Nov. 3 (Xinhua) -- Two Chinese spacecraft accomplished the country's first space docking procedure early Thursday, silently coupling in space more than 343 km above Earth's surface.Nearly two days after it was launched, the unmanned spacecraft Shenzhou-8 docked with space lab module Tiangong-1 at 1:36 a.m., marking another great leap for China's space program.The success of the docking procedure makes China the third country in the world, after the United States and Russia, to master the technique, moving the country one step closer to establishing its own space station.A video grab taken from the China Central Television on Nov.3, 2011 shows the Shenzhou-8 spacecraft docking with the Tiangong-1 space lab module. Unmanned spacecraft Shenzhou-8 docked with space lab module Tiangong-1 early Thursday, according to the Beijing Aerospace Control Center.President Hu Jintao, who is in France for the G-20 summit, sent a congratulatory message on the success of the country's first-ever space docking."Breakthroughs in and acquisition of space docking technologies are vital to the three-phase development strategy of our manned space program," Hu said in the message.Hu said he wishes all the program participants to try all out to fulfill a complete success of the whole mission after the smooth docking.Other leaders, including Wu Bangguo, Wen Jiabao, Li Changchun, Xi Jinping, Li Keqiang, He Guoqiang and Zhou Yongkang, who are Standing Committee members of the Political Bureau of the Communist Party of China Central Committee, watched the mission at the Beijing Aerospace Flight Control Center.China is now equipped with the basic technology and capacity required for the construction of a space station, said Zhou Jianping, chief designer of China's manned space program."This will make it possible for China to carry out space exploration on a larger scale," he said."The capability increases China's ability to act independently in space, as well as its ability to cooperate with others," said Gregory Kulacki, senior analyst and China project manager at the global security program of the Union of Concerned Scientists, a nonprofit scientific advocacy group based in the United States."China's pursuit of an original solution to space docking, that is based on their understanding of the experience of other nations, could lead to innovations or experiences other space-faring nations could find useful," Kulacki said.The world's first space docking was achieved in 1966, when the manned U.S. spacecraft Gemini 8 docked with an unmanned Agena Target Vehicle.Forty-five years later, the maneuver remains a technological challenge. Many of mankind's 300-plus attempts have been met with difficulties or resulted in failure."To link up two vehicles traveling at 7.8 km per second in orbit, with a margin of error of no more than 20 centimeters, is like 'finding a needle in a haystack'," Zhou said.The Shenzhou-8 and Tiangong-1 will separate after flying together for 12 days. After that a second docking procedure will be conducted.Rendezvous and docking, essential to exploring space beyond Earth's orbit, create the possibility of building space stations, resupplying them, transferring astronauts and rescuing them.Without this key know-how, exploration of the moon and beyond requires carrier rockets with significant amounts of thrust. China does not currently possess rockets of this magnitude.Shenzhou-8 and Tiangong-1 both weigh about 8 metric tons, well within the delivery capacity of the Long March 2F rocket. A permanent orbiting space station is designed to be as heavy as 60 metric tons, with docking ports accommodating both manned and freight space vehicles.The interior of both the Shenzhou-8 and Tiangong-1 is an actual environment in which astronauts can live and work. After the Shenzhou-8 tests, the Tiangong-1 will remain a target orbiter for more docking procedures in 2012 by the Shenzhou-9 and -10 spacecraft, at least one of which will be manned to conduct manual docking.Although the Shenzhou-8 is unmanned, it is equipped with devices to record images and data that will help China make improvements to its spacecraft design and astronaut training.Two female astronauts are now believed to be on the active duty roster for future Shenzhou missions, said Chen Shanguang, director of the Astronaut Center of China (ACC)."We must assess both male and female astronauts to verify if human beings can live in space, as there are huge differences between men and women in spite of their common generalities," Chen said."Space exploration activities would be incomplete without the participation of female astronauts," Chen said.The Chinese spacecraft also feature collaborative space experiments under the framework of a Chinese-German science and technology cooperation.German scientists designed bio-incubators for the experiments, while their Chinese counterparts were in charge of the development of control equipment, China's manned space program spokeswoman Wu Ping said.

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

WASHINGTON, Nov. 21 (Xinhua) -- The launch of the Mars Science Laboratory, which contains the car-sized Curiosity rover, has been delayed by a day to Nov. 26, the U.S. National Aeronautics and Space Administration (NASA) announced Monday.The delay will "allow time for the team to remove and replace a flight termination system battery," NASA said in a statement.The launch is now scheduled for 10:02 a.m. (1502 GMT) on Saturday from Cape Canaveral Air Force Station, Florida. The launch window remains open for one hour and 43 minutes.Curiosity is about twice as long and more than five times as heavy as any previous Mars rover. Its 10 science instruments include two for ingesting and analyzing samples of powdered rock delivered by the rover's robotic arm.Scheduled to land on the Mars in August 2012, the one-ton rover will examine Gale Crater during a nearly two-year prime mission. Curiosity will land near the base of a layered mountain three miles (five kilometers) high inside the crater. The rover will investigate whether environmental conditions ever have been favorable for development of microbial life and preserved evidence of those conditions.